Neurohormonal regulation and the overlapping pathology between heart failure and acute coronary syndromes

Reviews in Cardiovascular Medicine

Volumn 4, Issue SUPPL. 4, 2003, Pages

  Jesse, Robert L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Acute coronary syndromes; B type natriuretic peptide; Congestive heart failure; Ischemia; Left ventricular function; Myocardial function

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; ORBOFIBAN; TIROFIBAN;

ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; HEART DISEASE; HEART FAILURE; HEART INJURY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HORMONAL REGULATION; HUMAN; LUNG DISEASE; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN BLOOD LEVEL; SYMPTOMATOLOGY;

ACUTE DISEASE; CORONARY DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NEUROTRANSMITTER AGENTS; STROKE VOLUME; SYNDROME; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 0141960390     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Reimer KA, Lowe JE, Rasmussen MM, et al. The wave front phenomenon of ischemic cell death. Myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation. 1977;56:786-794.
2. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993; 329:1615-1622.
3. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA. 1993;270:1211-1216.
4. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications. Part 1. Circulation. 2001;104:2981-2989.
5. Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit a two year experience with 250 patients. Am J Cardiol. 1967;20:457-464.
6. Califf R. 1-year follow-up from the GUSTO-1 trial. Circulation. 1994;90:325-332.
7. de Lemos JA, Morrow DA, Bentley JA, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndrome. N Engl J Med. 2001;345:1014-1021.
8. Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI18. J Am Coll Cardiol. 2003;41:1264-1272.
9. Ross R, Glomset J, Harker L. Response to injury and atherogenesis. Am J Pathol. 1977;86:675-684.
10. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992;326:242-250.
11. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 1992;326:310-318.
12. Maisel AM, Krishnaswami P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
13. Tateishi J, Masutani M, Ohyanagi M, Iwasaki T. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol. 2000;23:776-780.
14. Omland T, de Lemos JA, Morrow DA, et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol. 2002;89:463-465.
15. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760-1763.
16. Kucher N, Gert P, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation. 2003;107:2545-2547.
17. Nakamura T, Sakamoto K, Yamano T, et al. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002; 39:1657-1663.